Literature DB >> 1341688

Zinc affects the metabolism of thyroid hormones in children with Down's syndrome: normalization of thyroid stimulating hormone and of reversal triiodothyronine plasmic levels by dietary zinc supplementation.

F Licastro1, E Mocchegiani, M Zannotti, G Arena, M Masi, N Fabris.   

Abstract

Levels of circulating thyroid stimulating hormone (TSH), tetraiodothyronine (T4), 3,5,3'-triiodothyronine (T3), and 3,3',5' triiodothyronine (reversal T3 or rT3) were measured in 25 children with trisomy of chromosome 21, also known as Down's syndrome (DS), and in 14 normal children. In subjects with DS TSH levels were increased, while plasmic levels of rT3 were decreased. No alteration in T3 and T4 levels was observed. Before zinc supplementation, plasmic levels of zinc and thymulin, a zinc dependent thymic hormone, were significantly decreased in DS children. After four months of dietary supplementation with zinc sulphate, a normalization of plasmic zinc, thymulin and TSH levels was observed. Plasmic levels of rT3 significantly increased, and after zinc treatment no difference was detectable between DS children and normal children. Clinical evaluation of the health status of DS children showed that zinc supplementation decreased the incidence of infectious diseases and improved school attendance. Thus, the increased efficiency of the immune system and the normalization of some endocrine parameters by zinc supplementation suggests that zinc deficiency may play a crucial role in some of the pathological manifestations associated with the syndrome, such as infections and malfunctioning of the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341688     DOI: 10.3109/00207459209003299

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.

Authors:  Cindy K Blair; Michelle Roesler; Yang Xie; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Leslie L Robison; Julie A Ross
Journal:  Paediatr Perinat Epidemiol       Date:  2008-05       Impact factor: 3.980

Review 2.  Relation Between Zinc and Thyroid Hormones in Humans: a Systematic Review.

Authors:  Jéssica Batista Beserra; Jennifer Beatriz Silva Morais; Juliana Soares Severo; Kyria Jayanne Clímaco Cruz; Ana Raquel Soares de Oliveira; Gilberto Simeone Henriques; Dilina do Nascimento Marreiro
Journal:  Biol Trace Elem Res       Date:  2021-01-07       Impact factor: 3.738

3.  Serum zinc levels and goitre epidemiology in Germany.

Authors:  R Hampel; T Kühlberg; K P Schneider; A Glass; H Zöllner
Journal:  Z Ernahrungswiss       Date:  1997-03

4.  Thyroid function and plasma immunoglobulins in subjects with Down's syndrome (DS) during ontogenesis and zinc therapy.

Authors:  M Sustrová; V Strbák
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

Review 5.  Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium.

Authors:  Amene Saghazadeh; Maryam Mahmoudi; Atefeh Dehghani Ashkezari; Nooshin Oliaie Rezaie; Nima Rezaei
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

6.  Metallothioneins (I+II) and thyroid-thymus axis efficiency in old mice: role of corticosterone and zinc supply.

Authors:  Eugenio Mocchegiani; Robertina Giacconi; Catia Cipriano; Nazzarena Gasparini; Fiorenza Orlando; Rosalia Stecconi; Mario Muzzioli; Gloria Isani; Emilio Carpenè
Journal:  Mech Ageing Dev       Date:  2002-03-31       Impact factor: 5.432

7.  Intrauterine Zn Deficiency Favors Thyrotropin-Releasing Hormone-Increasing Effects on Thyrotropin Serum Levels and Induces Subclinical Hypothyroidism in Weaned Rats.

Authors:  Viridiana Alcántara-Alonso; Elena Alvarez-Salas; Gilberto Matamoros-Trejo; Patricia de Gortari
Journal:  Nutrients       Date:  2017-10-18       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.